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palmitate-induced insulin resistance. Taken together, our re-
sults suggest that the ATX-LPA pathway contributes to obesity-
induced insulin resistance in metabolically relevant tissues.  
Our data also suggest that LPA directly impairs skeletal mus-
cle insulin signaling and mitochondrial function.—D’Souza, 
K., C. Nzirorera, A. M. Cowie, G. P. Varghese, P. Trivedi, 
T. O. Eichmann, D. Biswas, M. Touaibia, A. J. Morris, V. Aidinis, 
D. A. Kane, T. Pulinilkunnil, and P. C. Kienesberger. Auto-
taxin-LPA signaling contributes to obesity-induced insulin 
resistance in muscle and impairs mitochondrial metabolism. 
J. Lipid Res. 2018. 59: 1805–1817.
Supplementary key words  diet  effects/lipid  metabolism  •  glucose  • 
pyruvate • skeletal muscle • respiration
Autotaxin (ATX) is a lysophospholipase D that is also 
known as ecto-nucleotide pyrophosphatase/phosphodies-
terase family member 2 (ENPP2) (1), and generates the 
majority of extracellular lysophosphatidic acid (LPA) by 
hydrolyzing the lysophosphatidylcholine (LPC) contained 
Abstract Autotaxin (ATX) is an adipokine that generates 
the bioactive lipid, lysophosphatidic acid (LPA). ATX-LPA 
signaling has been implicated in diet-induced obesity and 
systemic insulin resistance. However, it remains unclear 
whether the ATX-LPA pathway influences insulin function 
and energy metabolism in target tissues, particularly skeletal 
muscle, the major site of insulin-stimulated glucose disposal. 
The objective of this study was to test whether the ATX-LPA 
pathway impacts tissue insulin signaling and mitochondrial 
metabolism in skeletal muscle during obesity. Male mice with 
heterozygous ATX deficiency (ATX+/) were protected from 
obesity, systemic insulin resistance, and cardiomyocyte dys-
function following high-fat high-sucrose (HFHS) feeding. 
HFHS-fed ATX+/ mice also had improved insulin-stimulated 
AKT phosphorylation in white adipose tissue, liver, heart, 
and skeletal muscle. Preserved insulin-stimulated glucose 
transport in muscle from HFHS-fed ATX+/ mice was associ-
ated with improved mitochondrial pyruvate oxidation in the 
absence of changes in fat oxidation and ectopic lipid accu-
mulation. Similarly, incubation with LPA decreased insulin-
stimulated AKT phosphorylation and mitochondrial energy 
metabolism in C2C12 myotubes at baseline and following 
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in lipoproteins and activated platelets (1–3). Despite its 
ubiquitous expression, a substantial proportion of circulat-
ing ATX emanates from the adipose tissue. Indeed, adi-
pose-specific ATX knockout mice exhibit 50% reduced 
plasma LPA (4, 5). ATX-LPA signaling through G protein-
coupled receptors (LPA1–6) influences many biological 
processes, including brain development, embryo implan-
tation, vasculogenesis, and hair follicle formation (6). 
Signaling effectors downstream of LPA receptors include 
PI3Kinase-AKT-Ras-related C3 botulinum toxin substrate 1 
activation, modulation of adenylate cyclase, stimulation of 
the mitogen-activated protein kinase pathway, Rho and 
Rho kinase activation, and stimulation of the phospholi-
pase C-protein kinase C pathway (7).
The ATX-LPA signaling axis plays an important role in 
many disease states, such as cancer, cardiovascular disease, 
neuropathic pain, pulmonary fibrosis, and arthritis (2, 
8–12). Notably, the ATX-LPA axis has been explored as a 
therapeutic target in diseases associated with chronic in-
flammation (13, 14). At least three compounds targeting 
the ATX-LPA pathway have passed phase I and II clinical 
trials for the treatment of idiopathic pulmonary fibrosis 
and systemic sclerosis (13, 15), demonstrating that modula-
tors of ATX-LPA receptor signaling have promising thera-
peutic potential. A recent study showed that genetic 
deletion or long-term pharmacologic inhibition of ATX in 
adult mice is well-tolerated, alleviating concerns that tar-
geting the ATX-LPA pathway could elicit toxicity (16).
The ATX-LPA pathway has also been implicated in obe-
sity and metabolic disease, specifically insulin resistance 
and impaired glucose homeostasis (4, 5, 17–22). In hu-
mans, serum ATX correlates with measures of obesity, im-
paired glucose homeostasis, and insulin resistance (19, 20). 
In addition, serum ATX is independently associated with 
hepatic steatosis, a metabolic complication of obesity and 
diabetes, in severely obese women (19). Studies in mice 
showed that ATX-LPA signaling influences adiposity, al-
though it remains incompletely understood whether the 
ATX-LPA pathway promotes or protects from diet-induced 
obesity and adipocyte hypertrophy (4, 5, 23). Dusaulcy 
et al. (4) showed that high-fat-fed adipose-specific ATX 
knockout mice have increased fat mass and adipocyte size. 
On the other hand, Nishimura et al. (5) demonstrated that 
adipose-specific and global heterozygous ATX knockout 
(ATX+/) mice are protected from high-fat diet-induced 
obesity (5). Brown adipose tissue (BAT) was functionally 
more active, resulting in increased energy expenditure in 
ATX-deficient mice (5). Moreover, ATX overexpression in 
mice led to augmented obesity following high-fat feeding 
(5, 23). Regardless of the effect of ATX-LPA on adiposity, 
studies using global heterozygous or fat-specific ATX 
knockout mice suggest that the ATX-LPA pathway contrib-
utes to high-fat diet-induced systemic insulin resistance 
and impaired glucose homeostasis (4, 5). Consistent with 
these studies, acute LPA injection resulted in impaired glu-
cose tolerance in chow- and high-fat diet-fed mice through 
inhibition of glucose-induced insulin secretion, an effect 
that was blunted by Ki16425, a preferential LPA1/3 antago-
nist (24). Prolonged administration of Ki16425 for 3 weeks 
enhanced glucose tolerance and insulin sensitivity in high-
fat diet-fed mice in the absence of changes in adiposity, 
which was mainly ascribed to increased islet cell number, 
glycogen storage in the liver, and muscle glucose oxida-
tion (24).
Despite growing evidence suggesting that the ATX-LPA 
pathway impacts glucose homeostasis and global insulin 
sensitivity in mice and humans, it remains unclear whether 
ATX-LPA signaling influences insulin sensitivity through 
direct or indirect effects of LPA on insulin target tissues. 
In particular, it is incompletely understood whether the 
ATX-LPA pathway modulates insulin function and energy 
metabolism in skeletal muscle, which accounts for the ma-
jority of insulin-mediated glucose disposal (25). Therefore, 
we examined tissue insulin signaling in mice with global 
heterozygous ATX deficiency subjected to diet-induced 
obesity and tested to determine whether the ATX-LPA 
pathway influences glucose and lipid metabolism in skele-
tal muscle.
Our study shows that: 1) partial ATX deficiency protects 
from impaired insulin signaling in white adipose tissue, 
liver, heart, and skeletal muscle following high-fat high-
sucrose (HFHS) feeding, as is reflected in reduced weight 
gain, improved glucose and insulin tolerance, and blunted 
cardiomyocyte dysfunction in male HFHS-fed ATX+/ mice; 
2) HFHS-fed ATX+/ mice are resistant to impaired insu-
lin-stimulated glucose transport in skeletal muscle and 
have improved mitochondrial pyruvate oxidation; and 
3) in C2C12 myotubes, incubation with LPA reduces insulin-
stimulated AKT phosphorylation at baseline and exacer-
bates palmitate-induced insulin resistance, coincident with 
impaired mitochondrial respiration. Taken together, these 
data suggest that the ATX-LPA pathway negatively regu-
lates muscle insulin signaling and mitochondrial function.
MATERIALS AND METHODS
Chemicals and reagents
Unless otherwise stated, chemicals and reagents were obtained 
from Sigma.
Animals
The generation of ATX+/ mice (C57Bl/6-Enpp2<tm1.1Vart>/
FLMG) and genotyping instructions have been previously re-
ported (26). Briefly, loxP-flanked neomycin selection cassettes 
were inserted upstream of exon 1 and downstream of exon 2 (26). 
Transgenic expression of Cre recombinase in mice bearing this 
allele resulted in excision of both exons, thus abolishing protein 
expression. Mice were housed on a 12 h light:12 h dark cycle with 
ad libitum access to chow diet (LD5001 from LabDiet with 
13.5 kcal% from fat) or HFHS diet (12451 from Research Diets 
with 45 kcal% from fat and 17 kcal% from sucrose) and water. 
Male and female mice (7–9 weeks old) were randomly assigned to 
chow or HFHS cohorts and fed for 20 weeks. For food intake stud-
ies, mice were individually housed and food consumption was 
monitored daily over a 5 day period 2 weeks post diet start. Mice 
were subjected to an insulin tolerance test (ITT) or glucose toler-
ance test (GTT) at 15 and 17 weeks post diet start, respectively. 
Peripheral fat accumulation in isofluorane-anesthetized mice was 
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determined by X-ray imaging using a Bruker In-Vivo Xtreme im-
ager 18 weeks post diet start. Planar X-ray images were analyzed 
using ImageJ software (National Institutes of Health) and area of 
peripheral fat was expressed as percent of total body area. Mice 
were euthanized by decapitation following a 3 h food withdrawal 
and tissues were collected. Perigonadal adipose tissue (PGAT) 
and BAT were weighed prior to being flash-frozen. EDTA-plasma 
was collected and spun at 15,600 g for 10 min at 4°C. For serum 
collection, blood was spun at 2,000 g for 15 min at 4°C. Plasma 
and serum were frozen and stored at 80°C until further use. All 
protocols involving mice were approved by the Dalhousie Univer-
sity Institutional Animal Care and Use Committee.
ITTs and GTTs
ITTs and GTTs were performed as previously described (27). 
For ITTs, awake mice were injected intraperitoneally with 1 U hu-
man insulin (HumulinR; Eli Lilly) per kilogram body weight fol-
lowing a 3 h food withdrawal. For GTTs, awake 16 h-fasted mice 
were injected intraperitoneally with 20% (w/v) D-glucose at 
2 g/kg body weight. Blood glucose was measured using an Aviva 
Nano glucometer (Accu-Chek).
Insulin signaling studies
For insulin signaling studies performed in vivo, mice were 
injected intraperitoneally with 10 U of insulin per kilogram 
body weight or an equal volume of saline. After 10 min, mice 
were euthanized and tissues were collected. For ex vivo insulin 
signaling studies in muscle, isolated soleus muscles were prein-
cubated for 30 min in pregassed (95% O2, 5% CO2) Krebs-
Henseleit bicarbonate buffer (KHB) (pH 7.4) (118.5 mM NaCl, 
4.7 mM KCl, 1.2 mM KH2PO4, 25 mM NaCHO3, 2.5 mM CaCl2, 
1.2 mM MgSO4, and 5 mM HEPES) at 37°C. Following subse-
quent incubation in buffer with or without 33 nM insulin for 
10 min, muscles were removed; connective tissue, fat, and ten-
dons were excised; and tissues were blotted dry and snap-frozen 
in liquid nitrogen.
Muscle glucose transport assay
Glucose transport in soleus muscle was determined ex vivo as 
previously described (27), with slight modifications. Soleus mus-
cles from mice were rapidly dissected, preincubated for 1 h in 
KHB containing 10 mM D-glucose at 37°C, and rinsed by incuba-
tion in KHB supplemented with 10 mM D-mannitol for 10 min. 
Glucose transport was assessed by incubation in KHB with 1 mM 
2-deoxyglucose, 9 mM mannitol, 1.5 Ci/ml 2-deoxy-D-[1,2-3H]
glucose (Perkin Elmer), and 0.3 Ci/ml D-[1-14C]mannitol (Per-
kin Elmer) for 20 min at 37°C. All buffers were pregassed with 
95% O2, 5% CO2 and were supplemented with saline or 33 nM 
insulin. Basal glucose transport and insulin-stimulated glucose 
transport were determined in contralateral muscles. Following 
the final incubation, muscles were cleaned by excising connective 
tissue, fat, and tendons, and tissues were blotted dry and snap-
frozen in liquid nitrogen. Muscles were weighed and digested 
for 30 min in 300 l of 1 N NaOH at 65°C and centrifuged at 
13,000 g for 10 min. Radioactivity in the supernatant was deter-
mined by liquid scintillation counting and glucose transport into 
tissues was calculated.
Gene expression analysis
RNA isolation, reverse transcription, and real-time quantitative 
PCR were performed as previously described (22, 28) using the 
following primer sequences: Glut1-forward (fwd) 5′-GGTGTG-
CAGCAGCCTGTGTACG-3′, Glut1-reverse (rev) 5′-TAGGACATC-
CAAGGCAGCCGTTC-3′, Glut4-fwd 5′-ACCGGCAGCCTCTGAT-
CATCG-3′, Glut4-rev 5′-GAGTGTCCGTCGTCCAGCTCGTT-3′, 
Rpl27-fwd 5′-ACGGTGGAGCCTTATGTGAC-3′, Rpl27-rev 5′-TC-
CGTCAGAGGGACTGTCTT-3′, Rpl41-fwd 5′-GCCATGAGAGC-
GAAGTGG-3′, and Rpl41-rev 5′-CTCCTGCAGGCGTCGTAG-3′.
Plasma and serum analysis
Serum insulin was determined using an ELISA kit assay (Crys-
tal Chem). NEFA (WAKO Chemicals) and triacylglycerol (TG) 
(Thermo Fisher Scientific) analyses were performed using colori-
metric kit assays, as per the manufacturer’s instructions. Plasma 
LPA levels were determined by HPLC/ESI/MS/MS analysis as 
previously described (29).
Cell culture
Insulin resistance was induced in C2C12 cells as previously de-
scribed (28). Briefly, cells were incubated in medium containing 
2% (w/v) fatty acid-free (FAF)-BSA and 0.8 mM sodium palmitate 
for 16–18 h. Myotubes were cultured with 2% FAF-BSA in the ab-
sence of palmitate to mimic an insulin-sensitive state. To examine 
insulin signaling, cells were incubated with 100 nM insulin or PBS 
for 15 min. Cells were washed once and harvested in ice-cold PBS, 
followed by centrifugation at 20,000 g for 10 min at 4°C. Cell pel-
lets were flash-frozen in liquid nitrogen and stored at 80°C until 
further use. For experiments involving LPA, 1-oleoyl-2-hydroxy-sn-
glycero-3-phosphate (18:1 LPA; Avanti) was dissolved in PBS with 
0.1% FAF-BSA, gently shaken, and mixed with DMEM-1X supple-
mented with 5 mM glucose prior to its addition to C2C12 myo-
tubes. Cells were cultured in the absence of serum during LPA 
treatment to avoid potential additional sources of LPA, LPC, 
and ATX.
Assessment of ATX activity
ATX activity in plasma and serum was quantified as previously 
described (22, 30). Briefly, 2 l of plasma or serum were added to 
18 l of buffer A containing 100 mM Tris-HCl (pH 9.0), 500 mM 
NaCl, 5 mM MgCl2, and 0.05% v/v Triton X-100. For samples ex-
amined in the presence of the ATX inhibitor, PF-8380 (31), 5 l 
of buffer A containing 10% DMSO or 5 mM of PF-8380 were 
added. Samples were preincubated at 37°C for 30 min and 25 l 
of 6 mM 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (14:0 
LPC; Avanti) were added. The reaction mixture was incubated at 
37°C for 6 h to allow for ATX-mediated choline release. Subse-
quently, 20 l of sample were incubated with 90 l of buffer C 
{9.65 ml of buffer B [100 mM Tris-HCl (pH 8.5) and 5 mM CaCl2], 
110 l of 30 mM N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylani-
line (TOOS; Cedarlane), 110 l of 50 mM 4-aminotipyrine, 6.6 l 
of 1,000 U/ml horseradish peroxidase, and 110 l of 300 U/ml 
choline oxidase} at 37°C for 20 min and choline oxidation was 
recorded at 550 nm for 30 min.
Immunoblotting analysis
Tissues and cells were homogenized in lysis buffer [20 mM Tris-
HCl (pH 7.5), 5 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, and 
1% NP-40] containing 2 mM sodium orthovanadate, 2 mM pro-
tease inhibitor cocktail (P8340; Sigma), and 100 g/ml phos-
phatase inhibitor cocktail (524628; Calbiochem) using a tissue 
homogenizer (Omni TH; Omni International) or by sonication, 
respectively. Protein concentrations in tissue and cell lysates or 
plasma were quantified colorimetrically using a BCA protein assay 
kit (Thermo Scientific) and BSA as standard. Lysates or plasma 
were subjected to SDS-PAGE and proteins were transferred onto 
a nitrocellulose membrane. Proteins were visualized using a re-
versible protein stain (Memcode; Pierce, Thermo Fisher Scien-
tific) and membranes were incubated with the following primary 
antibodies: anti-pAKT S473 (9271; Cell Signaling), anti-AKT (05-591; 
Millipore), anti-pp70S6K T389 (9234; Cell Signaling), anti-p70S6K 
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(2708; Cell Signaling), anti-pERK T202/Y204 (9101; Cell Signaling), 
anti-ERK (9102; Cell Signaling), anti-pJNK T183/Y185 (4688; Cell 
Signaling), and anti-c-Jun N-terminal kinase (JNK) (9252; Cell 
Signaling). Immunoblots were developed using the Western Light-
ning Plus-ECL enhanced chemiluminescence substrate (Perkin 
Elmer). Densitometric analysis was performed using Image Lab 
software (Bio-Rad).
Mitochondrial analysis
Respiratory oxygen flux in permeabilized soleus muscle fibers 
and C2C12 myotubes was measured in high-resolution using the 
Oxygraph-2k (OROBOROS Instruments). Permeabilized fibers 
were prepared as described (32). Briefly, soleus muscles were in-
cubated in ice-cold biopsy preservation solution [10 mM Ca-EGTA 
buffer, 0.1 M free Ca, 20 mM imidazole, 20 mM taurine, 50 mM 
K-MES, 0.5 mM DTT, 6.56 mM MgCl2, 5.77 mM ATP, and 15 mM 
phosphocreatine (pH 7.1)]. Excess connective tissue, fat, and ten-
dons were removed and fiber bundles were mechanically sepa-
rated using forceps. Fiber bundles were permeabilized in 2 ml of 
biopsy preservation solution containing 50 g/ml saponin and 
gently agitated on ice for 30 min. Thereafter, fiber bundles were 
washed in mitochondrial respiration medium (MiR05) buffer 
(0.5 mM EGTA, 3 mM MgCl2-6H2O, 60 mM lactobionic acid, 
20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose, 
and 1 g/l FAF-BSA); fiber wet weights were obtained; and samples 
were placed in the Oxygraph chambers. Samples were assessed in 
2 ml of hyper-oxygenated MiR05 buffer at 37°C and reoxygenated 
as necessary throughout the protocol. Instrumental background 
O2 consumption was corrected using equations determined un-
der the same parameters used for experimental data collection. 
C2C12 myotubes (200,000 cells/ml) were incubated with saline or 
10 M LPA for 16 h prior to cell permeabilization with 3 g/ml 
digitonin and mitochondrial respiration analysis. Thereafter, cells 
were collected and stored at 80°C until further analysis. The 
respirometric protocol for muscle fibers and C2C12 myotubes in-
volved the sequential addition of substrates, inhibitors, and/or ti-
tration of substrates, as indicated. Mitochondrial respiration was 
normalized to protein content, as determined by a BCA assay.
Citrate synthase activity assay
Citrate synthase activity was determined as previously described, 
with minor modifications (33). Permeabilized skeletal muscle fi-
bers or C2C12 cell pellets were homogenized in buffer containing 
20 mM HEPES, 10 mM EDTA, and 10 l/ml protease inhibitor 
(pH 7.4), and incubated on ice for 30 min. Samples were spun at 
600 g for 20 min at 4°C. An aliquot of the supernatant was used to 
determine protein concentration using a BCA assay. Homogenates 
were frozen for 1 h at 80°C to liberate citrate synthase from the 
mitochondrial matrix. The reaction was initiated by the addition 
of 227.5 l of reaction buffer containing 20 mM HEPES, 2 mM 
EGTA, 220 mM sucrose, 40 mM KCl, 0.1 mM DTNB, and 0.3 mM 
acetyl-CoA (pH 7.4) at 25°C. After 5 min, a baseline reading was 
obtained at 412 nm. The reaction was started by the addition of 
0.5 mM oxaloacetate and monitored at 412 nm for 10 min.
Tissue lipid analysis
For targeted lipidomic analysis in muscle, total lipids of weighed 
muscle tissue explants (50–100 mg) were extracted twice accord-
ing to Folch, Lees, and Sloane Stanley (34) using 4 ml chloro-
form/methanol (2/1, v/v) containing 500 pmol of butylated 
hydroxytoluene, 1% acetic acid, and 100 pmol of internal stan-
dards (d18:1/17:0 ceramide, 14:0-14:0 diacylglycerol (DG), 15:0-
15:0-15:0 TG; Avanti Polar Lipids) per sample. Extraction was 
performed under constant shaking for 90 min at room tempera-
ture. After addition of 800 l of dH2O and further incubation for 
30 min at room temperature, samples were spun at 1,000 g for 
15 min at room temperature to establish phase separation. The 
lower organic phase was collected, 2.5 ml of chloroform were 
added to the remaining aqueous phase, and the second extrac-
tion was performed as described above (30 min at room tempera-
ture with subsequent centrifugation). Combined organic phases 
of the double-extraction were dried under a stream of nitrogen 
and lipids were resolved in 150 l of 2-propanol/methanol/water 
(6/3/1, v/v/v) for UPLC-MS analysis. For protein determination, 
the interphase was dried and lysed using 1.5 ml NaOH/SDS 
(0.3 N/0.1%).
Chromatographic separation was modified after Knittelfelder 
et al. (35) using an AQUITY-UPLC system (Waters Corporation) 
equipped with a Kinetex EVO-C18 column (2.1 × 50 mm, 1.7 m; 
Phenomenex), starting a 15 min linear gradient with 100% sol-
vent A (methanol/water, 1/1, v/v; 10 mM ammonium acetate, 
0,1% formic acid, and 8 M phosphoric acid).
An EVOQ Elite™ triple quadrupole mass spectrometer (Bruker) 
equipped with an ESI source was used for detection. Lipid species 
were analyzed by selected reaction monitoring (DG: [MNH4]+ to 
[RCOO+58]+ of the respective esterified fatty acid, 15 eV, 50 ms; 
TG: [MNH4]+ to [DG-H2O]
+ of the respective DG, 23eV, 30 ms; 
Ceramide: [MH]+ to m/z 264.3, 22 eV, 60 ms; the resolution of 
Q1/Q3 were set to 0.7). Data were acquired with MS Workstation 
(Bruker). Data were normalized for recovery, extraction, and ion-
ization efficacy by calculating analyte/internal standard ratios 
(AU) and expressed as AU per milligram of tissue protein.
Analysis of TG accumulation in the liver (20 mg) was per-
formed using a colorimetric assay (Infinity Triglycerides reagent; 
Thermo Fisher Scientific) as previously described (36).
Adult ventricular cardiomyocyte culture and sarcomere 
shortening analysis
Cardiomyocytes were isolated from mice as previously de-
scribed (37). Cells were seeded on laminin-coated coverslips 
(4,000 cells/cm2) in plating medium. Following a 2 h incubation, 
cardiomyocytes were transferred to EBSS medium (Thermo 
Fisher Scientific) containing 1.25 mM Ca and electrically stimu-
lated at 1 Hz. Sarcomere dimensions during contractions were 
assessed using a PTI RatioMaster monochromator-based wide-
field microscope system (Horiba) in single cardiomyocytes. Sarco-
mere length, fractional shortening {[(sarcomere length at peak of 
relaxation – sarcomere length at peak of contraction)/sarcomere 
length at peak of relaxation] × 100}, sarcomere shortening rate, 
and sarcomere relengthening rate were determined.
Statistical analysis
Results are expressed as mean ± SEM. Comparisons between 
two groups were performed using an unpaired two-tailed Stu-
dent’s t-test. Comparisons between multiple groups were per-
formed using a paired or unpaired one- or two-way ANOVA 
followed by a Tukey or Sidak post hoc test, as appropriate. All 
statistical analysis was performed using Prism (GraphPad Soft-
ware). P values of less than 0.05 were considered statistically 
significant.
RESULTS
Male mice with heterozygous ATX deficiency have 
reduced obesity and improved glucose homeostasis on an 
obesogenic “Western” diet
Although prior studies have suggested that ATX haplo-
insufficiency or adipocyte-specific ATX deficiency improves 
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systemic glucose homeostasis in mice fed a high-fat diet, 
the effect of ATX deficiency on obesity and tissue insulin 
signaling remains unclear (4, 5). To clarify the role of ATX 
in diet-induced obesity, glucose metabolism, and insulin 
signaling, we fed male WT and ATX+/ mice chow or HFHS 
diet for 20 weeks. In agreement with previous studies (5, 
26), plasma LPA levels, ATX activity, and ATX protein con-
tent were markedly reduced in ATX+/ mice compared 
with WT mice (supplemental Fig. S1A–E). Body weights 
were similar between WT and ATX+/ mice immediately 
prior to HFHS feeding (WT, 22.45 ± 0.26 g; ATX+/, 22.30 
± 0.56 g; n = 15–18). However, HFHS-fed ATX+/ mice 
showed significantly reduced body weight gain compared 
with HFHS-fed WT mice, while food intake was unchanged 
between genotypes (Fig. 1A, B). In agreement with lower 
body weight gain, HFHS-fed ATX+/ mice showed reduced 
peripheral fat accumulation and PGAT and BAT weights 
(Fig. 1C–E). Furthermore, HFHS-fed ATX+/ mice had im-
proved glucose tolerance and insulin sensitivity, as assessed 
by a GTT and an ITT, respectively (Fig. 1F, G). ATX+/ 
mice were also protected from HFHS diet-induced hyper-
glycemia (Fig. 1H), hyperinsulinemia (Fig. 1I), and hyper-
triglyceridemia (Fig. 1J), while serum NEFA levels were 
similar between groups (Fig. 1K). Taken together, these 
data suggest that partial ATX deficiency protects from diet-
induced obesity and impaired glucose and lipid homeosta-
sis in male mice.
HFHS-induced body weight gain was much less pro-
nounced in female mice and was unchanged between gen-
otypes (supplemental Fig. S2A). Modest body weight gain 
in female HFHS-fed WT mice was associated with unchanged 
serum ATX activity (supplemental Fig. S2B) and insulin-
stimulated AKT phosphorylation in muscle when com-
pared with chow-fed mice (supplemental Fig. S2C, D). 
Therefore, subsequent studies were performed in male 
mice.
HFHS-fed ATX+/ mice have improved insulin signaling in 
liver, white adipose tissue, heart, and skeletal muscle
To examine whether enhanced tissue insulin function 
underlies the improvement in glucose homeostasis in HFHS-
fed ATX+/ mice, we performed in vivo insulin signaling 
analysis in metabolically relevant tissues. HFHS-fed WT 
mice developed insulin resistance in the liver and PGAT, as 
was evidenced by a 2- to 3-fold decrease in insulin-stimu-
lated phosphorylation of AKT at S473 (Fig. 2A, B). Impor-
tantly, insulin-stimulated AKT phosphorylation in the liver 
was significantly improved in HFHS-fed ATX+/ mice com-
pared with HFHS-fed WT mice, which was associated with 
reduced hepatic TG accumulation (supplemental Fig. 
S3E). Insulin-stimulated AKT phosphorylation was also un-
changed in the PGAT of HFHS-fed ATX+/ mice compared 
with chow-fed ATX+/ mice (Fig. 2A, B), suggesting that 
ATX+/ mice are resistant to HFHS diet-induced insulin 
resistance in liver and PGAT. These results corresponded 
with insulin-stimulated p70S6K phosphorylation at T389 
where p70S6K phosphorylation was higher in liver and 
PGAT from insulin-injected HFHS-fed ATX+/ mice com-
pared with WT mice (supplemental Fig. S3A–C).
We next examined insulin signaling in cardiac and skel-
etal muscle. As with the liver, HFHS-fed WT mice showed 
markedly impaired insulin-stimulated AKT and p70S6K 
Fig. 1. Partial ATX deficiency protects from HFHS diet-induced obesity and metabolic dysfunction in male mice. Body weight gain (A), 
food intake (B), peripheral fat accumulation (C), PGAT weight (D), BAT weight (E), GTT following an intraperitoneal injection with 
D-glucose at 2 g/kg body weight (F), and ITT following an intraperitoneal injection with human insulin at 1 U/kg body weight (G) in chow- 
and HFHS-fed WT and ATX+/ mice (n = 14–26). Blood glucose (H) and serum insulin (I), TGs (J), and NEFA (K) in chow- and HFHS-fed 
WT and ATX+/ mice following a 3 h food withdrawal (n = 5–13). A–K: Statistical analysis was performed using a two-way ANOVA followed 
by a Tukey’s multiple comparison test. A: *P < 0.05, **P < 0.01 versus ATX +/ HFHS. B–E, H–K: #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 
versus chow; *P < 0.05 as indicated. F, G: *P < 0.05, **P < 0.01, ***P < 0.001 for WT HFHS versus chow; $$P < 0.01 for ATX +/ HFHS versus 
chow.
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phosphorylation in the heart compared with chow-fed WT 
mice (Fig. 2A, D; supplemental Fig. S3A, D). AKT and 
p70S6K phosphorylation was unchanged in cardiac muscle 
from HFHS-fed ATX+/ mice compared with chow-fed con-
trols (Fig. 2A, D; supplemental Fig. S3A, D). Preserved 
insulin-stimulated AKT phosphorylation in hearts from 
HFHS-fed ATX+/ mice was associated with a resistance 
toward HFHS diet-induced contractile dysfunction in 
cardiomyocytes isolated from ATX+/ mice (Fig. 3A–E). 
HFHS feeding led to a decrease in fractional shortening, 
rate of contraction, and rate of relaxation in cardiomyo-
cytes from WT mice, but not ATX+/, mice (Fig. 3A–E).
Similar to cardiac muscle, insulin-stimulated AKT phos-
phorylation in the gastrocnemius and soleus muscle, which 
consist of primarily glycolytic and oxidative fibers, respec-
tively, was improved in HFHS-fed ATX+/ mice compared 
with WT mice (Fig. 4A–C). In addition, gastrocnemius 
and soleus muscles from HFHS-fed ATX+/ mice were 
Fig. 2. HFHS-fed ATX+/ mice show improved insulin signaling in liver, PGAT, and heart. Immunoblot and densitometric analysis of AKT 
phosphorylation at S473 in liver (A, B), PGAT (A, C), and heart (A, D) from chow- and HFHS-fed male WT and ATX+/ mice subjected to a 
3 h food withdrawal, followed by the intraperitoneal injection of saline or 10 U/kg insulin (n = 4–6). B–D: Statistical analysis was performed 
using a two-way ANOVA followed by a Tukey’s multiple comparison test. *P < 0.05, ***P < 0.001, ****P < 0.0001 versus saline; #P < 0.05, ##P < 
0.01, ####P < 0.0001 as indicated. C, chow; H, HFHS.
Fig. 3. Contractile properties are preserved in car-
diomyocytes from HFHS-fed ATX+/ mice. Sarcomere 
length (A), sarcomere shortening trace (mean) (B), 
fractional shortening (C), sarcomere shortening rate 
(D), and sarcomere relengthening rate (E) in ventricu-
lar cardiomyocytes isolated from chow- and HFHS-fed 
male WT and ATX+/ mice (n = 7–12 cardiomyocytes 
from two to three mice per group, 10 contractions per 
cardiomyocyte). Statistical analysis was performed us-
ing a two-way ANOVA followed by a Sidak multiple 
comparison test. A, C–E: *P < 0.05, **P < 0.01 versus 
chow; #P < 0.05, ##P < 0.01 as indicated.
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protected from impaired insulin-stimulated p70S6K phos-
phorylation (supplemental Fig. S3A, F, G). To determine 
whether improvements in skeletal muscle insulin signaling 
in HFHS-fed ATX+/ mice are maintained in the absence 
of circulating or neuronal factors, we performed insulin 
signaling analysis in soleus muscle ex vivo (Fig. 4A, D). Sim-
ilar to improved insulin signaling in gastrocnemius and so-
leus muscles from HFHS-fed ATX+/ mice in vivo (Fig. 
4A–C), insulin-stimulated AKT phosphorylation ex vivo 
was higher in soleus muscle from HFHS-fed ATX+/ mice 
than HFHS-fed WT mice (Fig. 4A, D). Furthermore, sus-
tained muscle insulin signaling in HFHS-fed ATX+/ mice 
was associated with preserved insulin-stimulation of glu-
cose transport in soleus muscle of HFHS-fed ATX+/ mice 
ex vivo, while the ability of insulin to stimulate glucose 
transport was reduced in soleus muscle from HFHS-fed WT 
mice compared with the chow control mice (Fig. 4E, F). In 
agreement with sustained insulin-stimulated glucose trans-
port in HFHS-fed ATX+/ mice, soleus muscle from ATX+/ 
mice was protected from HFHS-induced decline of Glut4 
mRNA levels (Fig. 4G), while Glut1 mRNA was unchanged 
between groups (Fig. 4H). Taken together, these data 
suggest that partial ATX deficiency protects against insulin 
resistance in metabolically active and insulin-responsive tis-
sues, including liver, white adipose tissue, myocardium, 
and skeletal muscle. Our data also suggest that sustained 
insulin signaling in the heart underlies, in part, the resis-
tance of cardiomyocytes from ATX+/ mice toward HFHS 
diet-induced contractile dysfunction. Moreover, our data 
suggest that preserved insulin stimulation of glucose trans-
port in skeletal muscle contributes to the improved sys-
temic glucose homeostasis in obese ATX+/ mice.
Improved insulin sensitivity in skeletal muscle  
of HFHS-fed ATX+/ mice is not associated with  
marked alterations in ectopic lipid accumulation
To explore possible mechanisms that underlie the blunted 
insulin resistance in skeletal muscle of HFHS-fed ATX+/ 
mice, we examined the accumulation of lipids that might 
contribute to obesity-induced muscle insulin resistance via 
lipidomic analysis in gastrocnemius muscle. Total ceramide 
levels were unchanged regardless of diet or genotype 
(Fig. 5A). When examining the major ceramide species, 
we noted a slight, but significant, decrease in unsaturated 
Fig. 4. HFHS-fed ATX+/ mice show improved insulin signaling in skeletal muscle in vivo and ex vivo. Immunoblot and densitometric 
analysis of AKT phosphorylation at S473 in gastrocnemius muscle (Gastrocn.) (A, B) and soleus muscle (A, C) from chow- and HFHS-fed male 
WT and ATX+/ mice subjected to a 3 h food withdrawal, followed by the intraperitoneal injection of saline or 10 U/kg insulin (n = 4–6). 
A, D: Immunoblot and densitometric analysis of AKT phosphorylation at S473 in soleus muscle isolated from chow- and HFHS-fed male WT 
and ATX+/ mice following incubation with saline or 33 nM insulin ex vivo (n = 3–5). Glucose transport rate (E) and fold stimulation (F) of 
glucose transport in soleus muscle from chow- and HFHS-fed male WT and ATX+/ mice incubated with saline or 33 nM insulin ex vivo. Gene 
expression analysis of Glut4 (G) and Glut1 (H) in soleus muscle from chow- and HFHS-fed male WT and ATX+/ mice (n = 7–10). B–H: 
Statistical analysis was performed using a two-way ANOVA followed by a Tukey’s multiple comparison test. B–E: *P < 0.05, ***P < 0.001, 
****P < 0.0001 versus saline; #P < 0.05, ####P < 0.0001 as indicated. F–H: *P < 0.05, **P < 0.01 versus chow. C, chow; H, HFHS.
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species (24:1) and a shift toward saturated (22:0) species in 
HFHS-fed compared with chow-fed mice of both genotypes 
(Fig. 5B). Total DG levels increased 2.5-fold in HFHS-fed 
versus chow-fed WT mice (Fig. 5C). Total DG levels were 
similar between genotypes in both chow- and HFHS-fed 
states, although DG concentrations were not significantly 
increased in HFHS-fed versus chow-fed ATX+/ mice (Fig. 
5C). When examining the DG acyl chain composition, we 
noted a HFHS diet-induced increase in 36:2 DGs in WT 
and ATX+/ mice, and a decrease in 32:0 and 38:4 DG spe-
cies in HFHS-fed compared with chow-fed ATX+/ mice 
(Fig. 5D). Total TG levels were increased in HFHS-fed WT 
and ATX+/ mice compared with the chow-fed controls 
and were similar between genotypes (Fig. 5E). TG species 
analysis revealed a HFHS diet-induced increase in TGs with 
longer acyl chains (54:2 and 54:3) and a decrease in TGs 
with shorter acyl chains (48:2 and 48:3) (Fig. 5F). The 48:3 
TGs were also changed between genotypes with lower lev-
els detected in chow- and HFHS-fed ATX+/ mice com-
pared with WT mice (Fig. 5F). Taken together, these data 
suggest that partial ATX deficiency modestly protects from 
obesity-induced increases in DG accumulation and results 
in altered TG species composition in skeletal muscle. These 
data also suggest that improved muscle insulin sensitivity in 
ATX+/ mice is not accompanied by major changes in mus-
cle lipid accumulation.
Improved glucose homeostasis in HFHS-fed ATX+/ mice 
is associated with enhanced mitochondrial function in 
skeletal muscle
To determine whether improved mitochondrial func-
tion contributes to the improved glucose homeostasis 
and insulin sensitivity in muscle of HFHS-fed ATX+/ mice, 
we performed high-resolution respirometric analysis of 
mitochondria from permeabilized soleus muscle fibers 
(Fig. 6A, B, D, E). Interestingly, during pyruvate oxidation, 
mitochondria from HFHS-fed ATX+/ muscle showed a 
significant increase in respiratory oxygen consumption fol-
lowing the addition of ADP and succinate compared with 
chow-fed ATX+/ and HFHS-fed WT controls (Fig. 6A). 
These changes were not evident in HFHS-fed WT mice. 
Uncoupled respiration, induced by addition of carbonyl 
cyanide p-trifluoro-methoxyphenyl hydrazine (FCCP), was 
also significantly elevated in HFHS-fed ATX+/ muscle fi-
bers (Fig. 6B). Increased mitochondrial respiration in the 
presence of pyruvate corresponded with increased citrate 
synthase activity in fibers from HFHS-fed ATX+/ mice 
(Fig. 6C), which is suggestive of elevated mitochondrial 
content (38). Mitochondrial respiration upon incubation 
with fatty acyl-carnitines was comparable between groups 
(Fig. 6D). Citrate synthase activity was reduced in fibers 
incubated with fatty acyl-carnitines and was not different 
between groups (data not shown), consistent with an in-
hibitory effect of fatty acyl esters on citrate synthase activity 
(39). Taken together, these data suggest that increased mi-
tochondrial glucose/pyruvate oxidation is associated with 
blunted insulin resistance in skeletal muscle and contrib-
utes to improved glucose homeostasis in HFHS-fed ATX+/ 
mice.
LPA impairs insulin signaling and exacerbates  
palmitate-induced insulin resistance in C2C12 myotubes
We next sought to investigate whether the resistance 
of ATX+/ mice toward obesity-induced impairment of 
skeletal muscle insulin signaling is due to a direct effect of 
LPA on skeletal muscle insulin function. C2C12 myotubes 
were incubated for 18 h in the absence or presence of 
1 and 10 M 1-oleoyl-LPA, mimicking physiological and 
Fig. 5. HFHS-fed ATX+/ mice do not show marked changes in skeletal muscle lipid accumulation. Levels of total ceramides (A), ceramide 
species (B), total DGs (C), DG species (D), total TGs (E), and TG species (F) in gastrocnemius muscle from chow- and HFHS-fed male WT 
and ATX+/ mice subjected to a 3 h food withdrawal (n = 8). A–F: Statistical analysis was performed using a two-way ANOVA followed by a 
Tukey’s multiple comparison test. *P < 0.05, **P < 0.01, ****P < 0.0001 versus chow; ##P < 0.01, ####P < 0.0001 as indicated.
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pathophysiological LPA concentrations (1, 4, 5, 40) (sup-
plemental Fig. S1A). Cells were also simultaneously incu-
bated in the absence or presence of 0.8 mM palmitate to 
induce insulin resistance, as determined by a 2-fold reduc-
tion in insulin-stimulated AKT phosphorylation at S473 (Fig. 
7A, B). At baseline, incubation with LPA impaired insulin-
stimulated AKT phosphorylation in C2C12 myotubes, simi-
lar to palmitate (Fig. 7A, B). Moreover, LPA exacerbated 
the palmitate-induced reduction in insulin-stimulated AKT 
phosphorylation (Fig. 7A, B). Prolonged treatment of 
C2C12 cells with LPA has been linked to the activation of 
JNK and ERK, both of which are associated with the devel-
opment of insulin resistance (41–43). Consistent with this 
notion, LPA-induced impairment of insulin function and 
exacerbation of palmitate-induced insulin resistance in 
C2C12 cells was associated with an upregulation of JNK 
and ERK phosphorylation (Fig. 7A, C, D). Taken together, 
these data suggest that exposure of muscle cells to LPA di-
rectly promotes the development of insulin resistance and 
worsens impaired insulin signaling induced by a lipotoxic 
milieu.
LPA impairs mitochondrial respiration in C2C12 
myotubes
To determine whether exogeneous LPA modulates mi-
tochondrial function in muscle cells, insulin-sensitive and 
insulin-resistant C2C12 myotubes were incubated with LPA 
and subjected to respirometric analysis (Fig. 8A, B). Insu-
lin-resistant C2C12 myotubes showed significantly reduced 
mitochondrial respiration in the presence of fatty acyl 
carnitines and pyruvate compared with insulin-sensitive 
cells (Fig. 8A). Addition of LPA in insulin-resistant myo-
tubes further depressed mitochondrial respiration (Fig. 
8A). LPA also had an effect on mitochondrial respiration 
in insulin-sensitive myotubes, leading to a significant re-
duction in pyruvate-supported mitochondrial O2 flow (Fig. 
8A). Moreover, LPA treatment significantly reduced un-
coupled respiration in insulin-resistant myotubes (Fig. 8B). 
In accordance with increased citrate synthase activity in 
muscle from HFHS-fed ATX+/ mice (Fig. 6C), incubation 
with LPA reduced citrate synthase activity in insulin-sensitive 
and insulin-resistant myotubes, consistent with impaired 
mitochondrial respiration (Fig. 8C). Taken together, these 
data suggest that LPA directly impairs mitochondrial func-
tion in C2C12 myotubes.
DISCUSSION
Recent studies have implicated the ATX-LPA axis in obe-
sity and impaired glucose homeostasis (4, 5, 19–21, 23). 
Improvements in obesity-induced insulin resistance and 
glucose intolerance in ATX mutant mice were primarily 
ascribed to changes in adipose tissue metabolism and func-
tion (4, 5). It remained unclear whether changes in insulin 
signaling and mitochondrial function in metabolically rel-
evant tissues contribute to the protective effect of ATX de-
ficiency toward the obesity-induced impairment of glucose 
homeostasis. In this study, we show that amelioration of 
obesity and systemic insulin resistance in HFHS-fed mice 
Fig. 6. Mitochondrial pyruvate oxidation is increased in skeletal muscle from HFHS-fed ATX+/ mice. Mitochondrial respiration (A, D) 
and uncoupled respiration (B, E) during pyruvate oxidation (A, B) and fatty acid oxidation (D, E) in permeabilized soleus muscle fibers 
from chow- and HFHS-fed male WT and ATX+/ mice. C: Citrate synthase activity in fibers subjected to pyruvate oxidation analysis (n = 5–6). 
A–E: Statistical analysis was performed using a two-way ANOVA followed by a Tukey’s multiple comparison test. ##P < 0.01 versus chow; 
*P <0,05, **P < 0.01, ****P <0.0001 as indicated. M, malate; Pyr, pyruvate; Palm, palmitoyl-carnitine; D, ADP; Oct, octanoyl-carnitine; 
R, rotenone; S, succinate; AmA, antimycin A.  at M
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with partial ATX deficiency is associated with increased in-
sulin signaling in metabolically active tissues, including 
liver, adipose tissue, and heart, as well as protection from 
obesity-induced cardiomyocyte dysfunction. In skeletal 
muscle, which accounts for the majority of insulin-stimu-
lated glucose disposal (25), partial ATX deficiency led to 
improvements in insulin signaling and insulin-stimulated 
glucose transport following HFHS feeding. In C2C12 myo-
tubes, LPA directly impaired insulin signaling and exacer-
bated palmitate-induced insulin resistance. Our data also 
show that the ATX-LPA axis influences mitochondrial me-
tabolism in muscle because partial ATX deficiency resulted 
in enhanced mitochondrial pyruvate/glucose oxidation in 
HFHS-fed mice and LPA directly decreased mitochondrial 
pyruvate/glucose oxidation in C2C12 myotubes. Impaired 
mitochondrial metabolism was paralleled by correspond-
ing changes in citrate synthase activity, an indicator of mi-
tochondrial function and abundance. Taken together, 
these data suggest that the ATX-LPA pathway plays an im-
portant role in the development of obesity-induced insulin 
resistance and impairs mitochondrial metabolism in skele-
tal muscle.
Only a few prior studies have examined the effect of 
ATX-LPA signaling on tissue insulin function (21, 24, 44). 
Rancoule et al. (24) showed that administration of a 
LPA1/3 receptor antagonist in high-fat diet-fed mice for 3 
weeks improves insulin sensitivity and increases insulin-
stimulated glucose oxidation in muscle ex vivo, suggesting 
Fig. 7. LPA impairs insulin signaling and exacerbates palmitate-induced insulin resistance in C2C12 myotubes. Immunoblot and densito-
metric analysis of AKT phosphorylation at S473 (A, B), ERK phosphorylation at T202/Y204 (A, C), and JNK phosphorylation at TT183/Y185 (A, D) 
in C2C12 myotubes incubated in the absence or presence of 0.8 mM palmitate and 0, 1, or 10 M LPA for 18 h, followed by stimulation with 
20 nM insulin for 15 min (n = 6). B–D: Statistical analysis was performed using a two-way ANOVA followed by a Tukey’s multiple comparison 
test. *P < 0.05, ****P < 0.0001 versus saline; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 versus no LPA controls. IS, insulin sensitive; IR, 
insulin resistant.
Fig. 8. LPA impairs mitochondrial respiration in 
C2C12 myotubes. Mitochondrial respiration (A), un-
coupled respiration (B), and citrate synthase activity 
(C) in permeabilized C2C12 myotubes incubated in 
the absence or presence of 0.8 mM palmitate and 0 or 
10 M LPA for 18 h (n = 5–6). A–C: Statistical analysis 
was performed using a two-way ANOVA followed by a 
Tukey’s multiple comparison test. *P < 0.05, **P < 
0.01, ****P < 0.0001 versus insulin sensitive; #P < 0.05, 
##P < 0.01, ####P < 0.0001 versus no LPA controls. IS, 
insulin sensitive; IR, insulin resistant. M1/2, malate; 
Palm, palmitoyl-carnitine; D, ADP; Oct, octanoyl-car-
nitine; Pyr, pyruvate; R, rotenone; S, succinate; AmA, 
antimycin A.
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that LPA signaling through LPA1/3 impairs muscle insulin 
function. However, other effects of systemic LPA1/3 inhi-
bition, including increased pancreatic islet mass and liver 
glycogen storage, may have contributed to changes in glu-
cose metabolism in muscle (24). Two very recent studies 
have provided more direct evidence for an inhibitory role 
of ATX-LPA signaling on tissue insulin function (21, 44). 
Acute pretreatment of primary rat hepatocytes with LPA 
decreased insulin-stimulated AKT phosphorylation, gluco-
kinase, and SREBP-1c expression, PI3K activation, and gly-
cogen synthesis, likely via LPA1 and/or LPA3 (44). 
Moreover, inhibition of ATX protected against interleukin 
6-induced impairment of insulin-stimulated AKT phos-
phorylation in 3T3-L1 adipocytes (21). We have previously 
shown that 24 h inhibition of ATX in 3T3-L1 adipocytes 
exposed to high glucose and insulin does not alter insulin 
resistance (22). However, it is possible that prolonged ATX 
inhibition is necessary to alter insulin signaling in this insu-
lin-resistant adipocyte model. In this study, we show that 
reduced ATX function ameliorates insulin resistance in 
adipose tissue, liver, heart, and skeletal muscle in vivo. In-
cubation with LPA directly impairs insulin signaling in 
myotubes, possibly through activation of JNK, ERK, or 
other stress kinases (41). Future studies should identify the 
LPA receptor(s) and precise mechanisms that mediate 
LPA-induced muscle insulin resistance. It is possible that 
G13, a mediator downstream of most LPA receptors (13), 
plays a role in the inhibition of muscle insulin function by 
LPA because G13 impairs muscle glucose uptake and sys-
temic insulin sensitivity in high-fat diet-fed mice (45).
Insulin resistance has been linked to altered mitochon-
drial function, although it remains uncertain whether 
changes in mitochondrial capacity are a cause or a conse-
quence of insulin resistance (46). The ATX-LPA axis ap-
pears to impair mitochondrial function in BAT (5, 23). 
Microarray analysis of primary BAT preadipocytes differ-
entiated with LPA or ATX inhibitor revealed that the 
ATX-LPA pathway decreases the expression of many genes 
involved in mitochondrial function (23). Consistent with 
this observation, a study employing mice with adipose-
specific ATX deficiency also suggested that the ATX-LPA 
pathway decreases mitochondrial content and membrane 
potential in BAT at baseline and following diet-induced 
obesity (5). However, it is presently unclear whether the 
ATX-LPA-induced decrease in mitochondrial function in 
BAT is secondary to changes in preadipocyte differentia-
tion (5, 23). Our study suggests that the ATX-LPA pathway 
plays a role in modulating mitochondrial function during 
insulin resistance by reducing oxidative metabolism and 
decreasing citrate synthase activity, an indicator of mito-
chondrial density, in muscle. Our data also suggest that 
partial ATX deficiency in vivo selectively increases mito-
chondrial pyruvate oxidation following diet-induced obe-
sity. Unaltered fat oxidation in muscle from HFHS-fed 
ATX+/ mice may explain the absence of major changes in 
muscle lipid accumulation, despite an overall decrease in 
obesity in these mice. Because we assessed muscle lipid ac-
cumulation in mice subjected to a 3 h food withdrawal, it 
remains to be determined whether lipid levels are also simi-
lar between genotypes following prolonged fasting. Never-
theless, these data confirm a study by Nishimura et al. (5) 
showing that ectopic fat accumulation in skeletal muscle, 
liver, and heart was similar in WT and ATX+/ mice with 
diet-induced obesity. Besides affecting insulin signaling, 
the ATX-LPA pathway has also been suggested to modulate 
other important processes in skeletal muscle, including the 
migration of satellite cells (47), secretion of chemokines 
(48), and regulation of intracellular calcium levels (49). It 
would be interesting to determine whether ameliorated in-
sulin resistance in skeletal muscle from ATX+/ mice is 
linked to changes in these processes in vivo.
Taken together, our study suggests that, in addition to 
reduced adipose tissue accumulation, improved insulin sig-
naling in adipose tissue, liver, and muscle contributes to 
preserved global insulin sensitivity in mice with partial ATX 
deficiency. Our data also suggest that the ATX-LPA path-
way directly impairs insulin signaling, insulin-stimulated 
glucose transport, and mitochondrial function in skeletal 
muscle (Fig. 9). Because impaired insulin signaling and 
metabolism in skeletal muscle are primary drivers of systemic 
insulin resistance and hyperglycemia (50), we propose that 
the obesity-induced upregulation of ATX and LPA recep-
tor signaling in muscle are critical mechanisms of insulin 
resistance. Therefore, modulators of the ATX-LPA pathway 
Fig. 9. Proposed role of the ATX-LPA axis in skeletal 
muscle insulin signaling and mitochondrial function. 
In diet-induced obesity, increases in ATX-LPA contrib-
ute to impaired skeletal muscle insulin signaling and 
glucose transport, a primary driver of systemic insulin 
resistance and type 2 diabetes. Inhibition of the ATX-
LPA pathway enhances skeletal muscle insulin sig-
naling, glucose transport, and mitochondrial glucose 
oxidation in an obesogenic milieu, thereby ameliorat-
ing diet-induced obesity and glucose homeostasis. GSV, 
Glut4 storage vesicles; P, phosphorylation; G, glucose.
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may present novel strategies toward the prevention and 
treatment of obesity-associated insulin resistance and type 
2 diabetes.
The authors thank Angella Mercer for technical assistance.
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